Skip to main content
. Author manuscript; available in PMC: 2021 Jul 1.
Published in final edited form as: Lancet HIV. 2020 Jun 1;7(7):e472–e481. doi: 10.1016/S2352-3018(20)30106-5

Table 3.

Rates of sexually transmitted infections experienced by HPTN 077 participants in the tail phase of the study compared to the injection phase

Tail phase (n=175*, person-years=181·2) Injection phase (n=177*, person-year=113·5) p-value
Incidence Rate (per 100 PY) 95% CI Incidence Rate (per 100 PY) 95% CI
Any STI 4·4 (1·9, 8·7) 6·2 (2·5, 12·7) 0·52
Urine
  C. trachomatis 1·7 (0·3, 4·8) 1·8 (0·2, 6·4)
  N. gonorrheae 1·1 (0·1, 4·0) 0·9 (0·0, 4·9)
Rectal
  C. trachomatis 0·6 (0·0, 3·1) 1·8 (0·2, 6·4)
  N. gonorrheae 0·6 (0·0, 3·1) 0·9 (0·0, 4·9)
Syphilis
  Incident 0·6 (0·0, 3·1) 0·9 (0·0, 4·9)
*

Two participants in the injection phase did not attend study visits during the tail phase.